Warning! GuruFocus detected
4 Severe warning signs
with EVT.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Evotec SE
ISIN : DE0005664809
Compare
Compare
Traded in other countries / regions
EVT.GermanyEVO.USA0IRF.UKEVT.BulgariaEVT.Austria1EVT.Italy IPO Date
2021-07-05Description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.81 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | -2.45 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.52 | |||||
| Beneish M-Score | -2.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.7 | |||||
| 3-Year EBITDA Growth Rate | -38.6 | |||||
| 3-Year FCF Growth Rate | -42.2 | |||||
| 3-Year Book Growth Rate | 12.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 40.77 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.06 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 1.19 | |||||
| 9-Day RSI | 2.24 | |||||
| 14-Day RSI | 3.16 | |||||
| 3-1 Month Momentum % | -3.57 | |||||
| 6-1 Month Momentum % | 32.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.09 | |||||
| Quick Ratio | 1.99 | |||||
| Cash Ratio | 1.13 | |||||
| Days Inventory | 18.26 | |||||
| Days Sales Outstanding | 53.2 | |||||
| Days Payable | 53.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -0.14 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 13.7 | |||||
| Operating Margin % | -12.7 | |||||
| Net Margin % | -22.05 | |||||
| FCF Margin % | -26.7 | |||||
| ROE % | -16.02 | |||||
| ROA % | -8 | |||||
| ROIC % | -5.11 | |||||
| 3-Year ROIIC % | -8.06 | |||||
| ROC (Joel Greenblatt) % | -23.78 | |||||
| ROCE % | -11.05 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 122.84 | |||||
| Shiller PE Ratio | 88.9 | |||||
| PS Ratio | 1.48 | |||||
| PB Ratio | 1.19 | |||||
| Price-to-Tangible-Book | 1.67 | |||||
| EV-to-EBIT | -6.34 | |||||
| EV-to-Forward-EBIT | -24.74 | |||||
| EV-to-EBITDA | -6.34 | |||||
| EV-to-Forward-EBITDA | 27.3 | |||||
| EV-to-Revenue | 1.56 | |||||
| EV-to-Forward-Revenue | 1.38 | |||||
| EV-to-FCF | -5.93 | |||||
| Price-to-GF-Value | 0.32 | |||||
| Price-to-Projected-FCF | 4.23 | |||||
| Price-to-Median-PS-Value | 0.21 | |||||
| Earnings Yield (Greenblatt) % | -15.78 | |||||
| FCF Yield % | -18.64 | |||||
| Forward Rate of Return (Yacktman) % | 24.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evotec SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil лв) | 1,530.159 | ||
| EPS (TTM) (лв) | -1.904 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 3.16 | ||
| 14-Day ATR (лв) | 0.216722 | ||
| 20-Day SMA (лв) | 7.1925 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (лв) | 5.15 - 10.17 | ||
| Shares Outstanding (Mil) | 177.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evotec SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evotec SE Stock Events
| Event | Date | Price (лв) | ||
|---|---|---|---|---|
| No Event Data | ||||
Evotec SE Frequently Asked Questions
What is Evotec SE(XBUL:EVT)'s stock price today?
The current price of XBUL:EVT is лв6.35. The 52 week high of XBUL:EVT is лв10.17 and 52 week low is лв5.15.
When is next earnings date of Evotec SE(XBUL:EVT)?
The next earnings date of Evotec SE(XBUL:EVT) is 2025-04-24 Est..
Does Evotec SE(XBUL:EVT) pay dividends? If so, how much?
Evotec SE(XBUL:EVT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers